Description
G17DT is a therapeutic cancer vaccine that targets gastrin-17, a hormone frequently overexpressed in colorectal cancer cells. This immunotherapy works by stimulating the patient's immune system to produce antibodies against gastrin-17, thereby blocking growth signals that promote tumor progression. G17DT has been evaluated in metastatic colorectal cancer both as monotherapy and in combination with chemotherapy agents like irinotecan.
Mechanism of Action
G17DT consists of gastrin-17 conjugated to diphtheria toxoid, which acts as an immunological carrier to enhance the immune response. When administered, it induces the formation of antibodies against gastrin-17, neutralizing this growth hormone and potentially reducing tumor cell proliferation and angiogenesis in gastrin-17 expressing colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
| Administration | Intramuscular |
| Clinical Trials | 5 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.